Skip to main content

Generics

  • Study finds widespread disparities in medication use

    LEBANON, N.H. — Medicare beneficiaries' use of medications — both effective and risky — varies widely across different regions of the United States, according to a new report.

  • Walgreens flu survey: Last year's season packed a wallop

    DEERFIELD, Ill. — The 2012-2013 flu season was one of the most severe in the United States in more than a decade and, according to a new study, had two to three times the impact than a more typical flu season on the workplace, school, family and other segments of people’s everyday lives. A new report from Walgreens released Wednesday suggests U.S. adults missed 230 million work days last season, while children lost more than 90 million school days due to flu-related illness.  

  • Actavis seeks approval for generic opioid-dependence drug

    DUBLIN — Actavis is hoping to become the first to market a generic version of a drug used to treat patients who have become dependent on opioid drugs, triggering a lawsuit from the branded drug's manufacturer.

    The generic drug maker said it had filed a regulatory approval application with the Food and Drug Administration for buprenorphine hydrochloride and naloxone hydrochloride sublingual film in the 2-mg/0.5-mg and 8-mg/2-mg strengths. The drug is a generic version of Reckitt Benckiser's Suboxone.

  • NCPIE outlines steps to improve adherence among elderly, polychronic patients

    WASHINGTON — Calling it a "looming threat," the National Council on Patient Information and Education released a 10-step plan to draw attention to the problem of poor medication adherence among elderly people with multiple chronic conditions.

  • FDA approves Teva antibiotic

    JERUSALEM — The Food and Drug Administration has approved a new generic drug from Teva Pharmaceutical Industries for treating eye infections, the company said.

    The Israeli drug maker announced the approval of the antibiotic drug tobramycin inhalation solution, a generic version of Novartis' Tobi.

    Tobi has sales of about $350 million during the 12-month period that ended in June, according to IMS Health.

     

  • Study finds widespread nonadherence among schizophrenia patients

    NEW YORK — Nearly half of patients with schizophrenia don't comply with doctors' prescription instructions, according to a new physician survey.

  • Independents increase role in promoting adherence, generics

    ORLANDO, Fla. — Independent pharmacies are focusing more on helping patients adhere to their medication therapies and save money by using generics, according to a new digest for members of a trade group that represents independents.

  • Calif. bill to restrict biosimilars gets governor's veto

    NEW YORK — The governor of California has vetoed a bill that critics said would have limited patients' access to knock-off versions of biotech drugs.

X
This ad will auto-close in 10 seconds